

APR 13 2007

Page 1 of 2

K070851

510(k) Summary

**ArthroCare Corporation
ArthroCare® ArthroWand™**

FDA/CDRH/ODE/PMO
2007 MAR 28 A 9:41
RECEIVED

General Information

Submitter Name/Address: ArthroCare Corporation
680 Vaqueros Avenue
Sunnyvale, CA 94085-2936

Establishment Registration Number: 2951580

Contact Person: Valerie Defiesta-Ng
Director, Regulatory Affairs

Date Prepared: March 27, 2007

Device Description

Trade Name: ArthroCare® SpineWand™

Generic/Common Name: Electrosurgical Device and Accessories

Classification Name: Electrosurgical Cutting and Coagulation
Device and Accessories (21 CFR
878.4400)

Predicate Devices

ArthroCare Wands	K060823 (April 10, 2006)
ArthroCare System 2000	K001588 (August 17, 2000)

Product Description

The Wands are bipolar, single use, high frequency electrosurgical devices.

Intended Use

The Wands are intended for resection, ablation, and coagulation of soft tissue and hemostasis of blood vessels in orthopedic, arthroscopic, spinal, and neurological procedures.

K 070851

Page 2 of 2

Substantial Equivalence

This Special 510(k) proposes modifications to the packaging and labeling of the ArthroCare Wands. The indications for use, materials, technology, sterilization, principle of operation, and performance specifications of the Wands remain the same as in the predicate cleared 510(k).

Summary of Safety and Effectiveness

The proposed modifications to the Wands are not substantial changes, and do not significantly affect the safety or efficacy of the predicate devices.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

ArthroCare Corporation
% Ms. Valerie Defiesta-Ng
Director, Regulatory Affairs
680 Vaqueros Avenue
Sunnyvale, California 94085-2936

APR 13 2007

Re: K070851

Trade/Device Name: ArthroCare® SpineWand™

Regulation Number: 21 CFR 878.4400

Regulation Name: Electrosurgical cutting and coagulation device and accessories

Regulatory Class: II

Product Code: GEI, GXI

Dated: March 27, 2007

Received: March 28, 2007

Dear Ms. Defiesta-Ng:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Mark N. Melkerson', with a stylized flourish at the end.

Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure


Indications for Use Statement

510(k) Number: K 070851

Device Name: ArthroCare® SpineWand™

Indications for use:

The Wands are intended for resection, ablation, and coagulation of soft tissue and hemostasis of blood vessels in orthopedic, arthroscopic, spinal, and neurological procedures



(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices

510(k) Number 16070851

Prescription Use
(Part 21 CFR 801
Subpart D)

X

AND/OR

Over-the-Counter Use
(21 CFR 807 Subpart
C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)